Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

Osteogenesis imperfecta (OI) is a heritable disease, which results from an abnormal amount or structure of Type I collagen. Bisphosphonates, a class of synthetic antiresorptive drugs, used in osteoporosis management, are also used to decrease fracture incidence and improve quality of life in children with OI. In this study, we used the oim mouse to test the hypotheses that pamidronate treatment during active growth (1) produces larger, stronger, stiffer long bone diaphyses without altering bone material properties, and (2) negatively impacts longitudinal bone growth. Our results indicate that femoral cross-sectional moment of inertia in the distal metaphysis tended to increase with pamidronate treatment and that the treated bones are thicker and structurally stiffer, but shorter than their control-dose counterparts.